Psychedelic medicine is about to blow up
Fast Company, May 11, 2021
New clinical data shows that MDMA-assisted therapy can have a significant impact on PTSD, paving the way for FDA approval and commercialization.
Who’s in Charge of Psilocybin?
Chacruna, May 10, 2021
From clinicians and investors to Indigenous groups and activists, debate is raging over whether psychedelics are spiritual tools, new psychiatric drugs, medicines for social change, or all of the above.
The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.
The New York Times, May 9, 2021
Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences.
Legalise ‘magic mushrooms’ to help cure depression, says London scientist
My London, May 6, 2021
The director of a pioneering psychedelic research centre on the benefits and limitations of psychedelics for depression.
MAPS’ Phase 3 Trial of MDMA-Assisted Therapy for PTSD Achieves Successful Results for Patients with Severe, Chronic PTSD
MAPS, May 3, 2021
The first Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) replicated and expanded on Phase 2 results indicating MDMA-assisted therapy may be an effective and cost-saving treatment for PTSD resulting from any cause.
A Psychedelic Drug Passes a Big Test for PTSD Treatment
The New York Times, May 3, 2021
A new study shows that MDMA can bring relief when paired with talk therapy to those with severe post-traumatic stress disorder.
There Is a Lot of Fungus Among Us
The New York Times, April 24, 2021
Coffee for immune support. Supplements for inflammation. And psychedelics promising relief from serious ailments. Mushrooms are everywhere, and investors are paying attention.
Massachusetts General Hospital Launches Center to Study Neuroscience of Psychedelics
The Crimson, April 23, 2021
Massachusetts General Hospital, an affiliate of Harvard Medical School, launched a new center to study the clinical benefits of psychedelics in treating mental illness.
Psychedelics are transforming the way we understand depression and its treatment
The Guardian, April 20, 2021
Psychiatry has long failed to explain depression. Our research into psilocybin suggests a new approach could offer answers.
Psilocybin least as good as antidepressant in UK study
Reuters, April 15, 2021
A study published in the New England Journal of Medicine, psilocybin could be as effective as a leading antidepressant—and while more research is still required, the study’s lead author says the results should give people hope for functional alternatives to SSRIs.
New $6.4M research program to advance psychedelics research and treatments
Eurek Alert, March 30, 2021
Psychedelics research in support of brain health is getting a major boost this month with the formation of the Neuroscape Psychedelics Division at the University of California, San Francisco (UCSF).
Suing the DEA for Access to Psilocybin
Mushroom Revival, March 24, 2021
A Seattle based doctor, Dr. Sunil Aggarwal, has filed a lawsuit against the DEA for denying him permission to use psilocybin therapy in his palliative care.
Psychedelic for meth users: Sydney trial aims to conquer addiction
Sydney Morning Herald, March 22, 2021
A world-first clinical trial in Sydney aims to find out if giving psychedelics to people who use methamphetamines can help conquer their addiction.
Researchers at St Vincent’s Hospital in Darlinghurst will use psilocybin to turbocharge therapy for patients dependent on “meth” or “ice”.
Can Magic Mushrooms Heal Us?
The New York Times, March 18, 2021
A very promising mental health experiment is taking shape in Oregon.
Australian Government to Spend $15m on Psychedelic Trials
Vice, March 17, 2021
The Australian government will fund a series of clinical trials into the potential use of psilocybin, MDMA, ketamine and other drugs as treatments for debilitating mental illnesses. The $15 million Innovative Therapies for Mental Illness Grant Opportunity aims to bolster Australian-led research into drug and psychedelic-assisted psychotherapy.
‘Better treatments’: Government to fund psychedelic drugs trials to treat mental illness
Sydney Morning Herald, March 17, 2021
Clinical trials using magic mushrooms, ecstasy and other psychedelic drugs in potential breakthrough therapies for debilitating mental illnesses will be funded by the Australian federal government as part of global efforts to advance innovative treatments. The Morrison government launched a $15 million competitive grant round to kick-start Australian clinical trials of potential breakthrough combination therapies.
Psychedelic therapy could ‘reset’ depressed brain
BBC News, March 16, 2021
A powerful hallucinogenic medicine known for its part in shamanic rituals is being trialled as a potential cure for depression for the first time.
Creso Pharma Acquisition of Psychedelic Company Halucenex Life Sciences Inc.
Vancouver Sun, March 15, 2021
Creso Pharma has announced a transformational move to evolve from a medical cannabis company to an integrated natural medicines provider with the acquisition of Canadian psychedelics company, Halucenex Life Sciences Inc.
New Legion Veterans Village in Surrey will include centre to research medical psychedelics
Small Caps, March 13, 2021
Surrey will soon be home to a research centre that brings together experts in medical cannabis and psychedelics to help people with post-traumatic stress disorder.
Suicide warning over denied drugs
The Australian, March 9, 2021
Delaying mental practitioners access to psilocybin and MDMA could result in a spike in suicides amid an ongoing national mental health crisis, according to advocates for psychedelic-assisted therapy.